Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients

Supportive Care in Cancer

Volumn 16, Issue 7, 2008, Pages 841-846

  De Souza Viana, Luciano ^a,b,c   Serufo, José Carlos ^a   Da Costa Rocha, Manoel Otávio ^a   Costa, Renato Nogueira ^b   Duarte, Roberto Carlos ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b HOSPITAL FELÍCIO ROCHO   (Brazil)

^c NONE   (Brazil)

Author keywords

Fever; Infections; Neutropenia; Neutropenic fever

Indexed keywords

ANTIBIOTIC AGENT;

ACCURACY; ADULT; ARTICLE; CANCER PATIENT; CAUSE OF DEATH; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTINATIONAL ASSOCIATION OF SUPPORTIVE CARE IN CANCER INDEX SCORE; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SOLID TUMOR;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; FEMALE; FEVER; HEALTH STATUS INDICATORS; HUMANS; INFECTION; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 44949102248     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0347-3     Document Type: Article

References (15)

1. Chamilos G, Bamias A, Efstathiou E et al (2005) Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 103(12):2629-2635
2. Cherif H, Johansson E, Bjorkholm M et al (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91(2):215-222
3. Donowitz GR, Maki DG, Crnich CJ, et al (2001) Infections in the Neutropenic Patient - New Views of an Old Problem. In: ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, 43TH., 2001, Orlando. Education Program Book: Hematology (Am Soc Hematol Educ Program):113-139
4. Elting LS, Rubenstein EB, Rolston KV et al (1997) Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25(2):247-259
5. Escalante CP, Weiser MA, Manzullo E et al (2004) Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer 12(9):657-662
6. Hughes WT, Armstrong D, Bodey GP et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730-751
7. Kern WV (2006) Risk assessment and treatment for low-risk patients with febrile neutropenia. Clin Infect Dis 42(4):533-540
8. Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038-3051
9. Nijhuis CO, Kamps WA, Daenen SM et al (2005) Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 23(30):7437-7444
10. Paesmans M (2000) Risk factors assessment in febrile neutropenia. Int J Antimicrob Agents 16(2):107-111
11. Sipsas NV, Bodey GP, Kontoyiannis DP (2005) Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 103(6):1103-1113
12. Rolston KV (2003) Oral antibiotic administration and early hospital discharge is a safe and effective alternative for treatment of low-risk neutropenic fever. Cancer Treat Rev 29(6):551-554
13. Rolston KV (1999) New trends in patient management: Risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 29(3):515-521
14. Talcott JA, Finberg R, Mayer RJ et al (1988) The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148(12):2561-2568
15. Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12(8):555-560